Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dexamethasone Late Clear all
Completed Phase 1 Interventional

Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)

NCT01926665
View directory record Official record
Conditions
Lymphoma
Interventions
Carfilzomib, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 5, 2026, 4:42 AM EDT
Withdrawn Phase 3 Interventional

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT03334487
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Dexamethasone, Rovalpituzumab tesirine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
27
States / cities
Chandler, Arizona • Scottsdale, Arizona • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 5, 2026, 4:42 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

NCT00002816
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, dexamethasone, etoposide, idarubicin, ifosfamide, leucovorin calcium, mesna, pegaspargase, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy, Methotrexate
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
30
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Sep 5, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

NCT01273480
View directory record Official record
Conditions
Neoplasm Metastases
Interventions
Sequence 1, Sequence 2
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Sep 5, 2026, 4:42 AM EDT
Completed Phase 3 Interventional

Dexamethasone Therapy in VLBW Infants at Risk of CLD

NCT00011362
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
Interventions
Dexamethasone Early, Dexamethasone Late
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
13 Days to 15 Days
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1994
U.S. locations
13
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 5, 2026, 4:42 AM EDT
Not yet recruiting Phase 3 Interventional

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 5, 2026, 4:42 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking

NCT06235567
View directory record Official record
Conditions
Keratoconus
Interventions
Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops
Drug
Lead sponsor
Maanasa Indaram, MD
Other
Eligibility
13 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 5, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

NCT00669877
View directory record Official record
Conditions
Burkitt's Lymphoma, Burkitt'S-like Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, G-CSF, Cytarabine, Methotrexate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 5, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)

NCT00591643
View directory record Official record
Conditions
Adrenal Tumors, Adrenal Malignancies, Abnormal Hormonal Secretions, Electrolytes Abnormalities
Interventions
Imaging, Adrenal acans, (NP-59)
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1977 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced Sep 5, 2026, 4:42 AM EDT
Terminated Phase 4 Interventional Results available

An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women

NCT05038878
View directory record Official record
Conditions
Mild Autonomous Cortisol Excess
Interventions
Elagolix
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 5, 2026, 4:42 AM EDT
Completed Phase 3 Interventional Results available

Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial

NCT02623426
View directory record Official record
Conditions
Uveitis, Macular Edema
Interventions
Dexamethasone intravitreal implant 0.7 mg, Intravitreal Methotrexate 400 µg, Intravitreal Ranibizumab 0.5 mg
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Sep 5, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01412879
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bendamustine hydrochloride, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, methotrexate, vincristine sulfate
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
204
States / cities
Duarte, California • Aurora, Colorado • Boulder, Colorado + 142 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 5, 2026, 4:42 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Talquetamab, Daratumumab, Teclistamab, Bortezomib, Lenalidomide, Dexamethasone, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Duarte, California • San Francisco, California • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 4:42 AM EDT
Completed Not applicable Interventional Results available

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

NCT00096135
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
18 Months to 29 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
135
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 5, 2026, 4:42 AM EDT
Completed Phase 2 Interventional

Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma

NCT00375791
View directory record Official record
Conditions
Multiple Myeloma
Interventions
perifosine, dexamethasone
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
Berkeley, California • Duarte, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 5, 2026, 4:42 AM EDT
Recruiting Phase 3 Interventional

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

NCT06022939
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration
Procedure · Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
117
States / cities
Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 5, 2026, 4:42 AM EDT
Recruiting Phase 1 Interventional

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

NCT05581030
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 5, 2026, 4:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

NCT02186834
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Liposomal doxorubicin, Dexamethasone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Tampa, Florida • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 5, 2026, 4:42 AM EDT
Active, not recruiting Phase 2 Interventional

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

NCT03004287
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Thalidomide, Dexamethasone, Daratumumab, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide, Melphalan, ASCT, Lenalidomide, Bortezomib
Drug · Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 5, 2026, 4:42 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Cyclophosphamide, Induction therapy, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
San Francisco, California • Tampa, Florida • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 4:42 AM EDT
Enrolling by invitation Phase 4 Interventional

Laparoscopic TAP Block During Robotic Assisted Laparoscopic Radical Prostatectomy for Improvement in Postoperative Pain

NCT05753046
View directory record Official record
Conditions
Prostate Cancer
Interventions
Early TAP Block, Late TAP Block
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older · Male only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 5, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma

NCT00166439
View directory record Official record
Conditions
Lymphoma
Interventions
Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)
Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 5, 2026, 4:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome

NCT00989781
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
3-D Ultrasound, recombinant human chorionic gonadotropin, Recombinant human follicle stimulating hormone, Adrenocorticotropin, Dexamethasone, Glucose
Radiation · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 5, 2026, 4:42 AM EDT
Terminated Phase 1 Interventional

Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears

NCT01688362
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Platelet Rich Plasma (PRP), Corticosteroid
Biological · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 5, 2026, 4:42 AM EDT